Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-01-03
2006-01-03
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S021800, C530S308000, C530S324000, C530S350000, C424S198100, C424S278100
Reexamination Certificate
active
06982248
ABSTRACT:
Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagon-like peptide-1. The invention relates to both the method and compositions for such treatment.
REFERENCES:
patent: 4196196 (1980-04-01), Tlholtz
patent: 4976959 (1990-12-01), Berger, Jr. et al.
patent: 5424286 (1995-06-01), Eng
patent: 5955594 (1999-09-01), Mishra
patent: 6107329 (2000-08-01), Hoover et al.
patent: 6410513 (2002-06-01), Galloway et al.
patent: 2002/0061838 (2002-05-01), Holmquist et al.
patent: WO 94/15925 (1994-07-01), None
patent: WO 98/02273 (1998-01-01), None
patent: WO 98/08531 (1998-03-01), None
patent: 98/43658 (1998-10-01), None
patent: 00/16797 (2000-03-01), None
Tibaduiza, E. C. (2001) A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J. Biol. Chem. vol. 276, pp. 37787-37793.
Abbott et al., “The Impact of Diabetes on Survival Following Myocardial Infarction in Men vs. Women-The Framingham Study”,JAMA, vol. 260 No. 23, pp. 3456-3460 (1988).
Bhat et al., “Skeletal Muscle Mitochondrial DNA Injury in Patients With Unilateral Peripheral Arterial Disease”,Circulation, vol. 99, pp. 807-812 (1999).
Boska et al., “31P MRS Studies of Exercising Human Muscle at High Temporal Resolution”,Magnetic Resonance in Medicine, vol. 41, pp. 1145-1151 (1999).
Brand et al., “Diabetes, Intermittent Claudication, and Risk of Cardiovascular Events -The Framingham Study”, Diabetes, vol. 38, pp. 504-509 (1989).
Bulllock et al., “Tissue Distribution of Messenger Ribonucleic Acid Encoding the Rat Glucagon-Like Peptide-1 Receptor”,Endocrinology, vol. 137, No. 7, pp. 2968-2978 (1996).
Clanton et al., “Physiological and Genomic Consequences of Intermittent HypoxiaInvited Review: Adaptive Responses of Skeletal Muscle to Intermittent Hypoxia: the Known and the Unknown”,J. Appl. Physiol, vol. 90, pp. 2476-2487 (2001).
Dawson et al., “A Comparison of Cilostazol and Pentoxifylline for Treating Intermittent Claudication”,The American Journal of Medicine, vol. 109, pp. 523-530.
DuPont et al., “Marijuana and Benzodiazepines in Patients Receiving Methadone Treatment”,JAMA, vol. 261, No. 23, pp. 3409 (1989).
Gray et al., “Risk Factor Clustering in the Insulin Resistance Syndrome-The Strong Heart Study”,American Journal of Epidemiology, vol. 147, No. 9, pp. 869-878 (1998).
Green, “Regarding ‘Phosphorus 31 Nuclear Magnetic Resonance Spectroscopy Suggests a Mitochondrial Defect in Claudicating Skeletal Muscle’”,Journal of Vascular Surgery Online, vol. 33, No. 5, pp. 1-2 (2001).
Hamilton et al., “Insulin Reduction of Cerebral Infarction Due to Transient Focal Ischemia”,J. Neurosurg., vol. 82, pp. 262-268 (1995).
Hiatt et al., “Carnitine Metabolism During Exercise in Patients with Peripheral Vascular Disease”,J. Appl. Physiol., vol. 62, No. 6, pp. 2383-2387 (1987).
Iribarren et al., “Glycemic Control and Heart Failure Among Adult Patients with Diabetes”,Circulation, vol. 103, pp. 2668-2673 (2001).
Irwin et al., “The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties”,Proc. Natl. Acad. Sci. USA, vol. 94, pp. 7915-7920 (1997).
Matz, “Does Control of Diabetes Prevent Vascular Complication?”,JAMA, vol. 261, No. 23, pp. 3409-3410 (1989).
Reilly et al., “Cilostazol: Treatment of Intermittent Claudication”,The Annals of Pharmacotheraphy, vol. 35, pp. 48-56 (2001).
Scott et al., “Glucose and Insulin Therapy in Acut Stroke; Why Delay Further?”,O J Med, vol. 91, pp. 511-515 (1998).
Serre et al., “Exendin-(9-39) is an Inverse Agonist in the Murine Glucagon-Like Peptide-1 Receptor: Implications for Basal Intracellular Cyclic Adenosine 3', 5',-Monophosphate Levels and β-Cell Glucose Competence”,Endocrinology, vol. 139, No. 11, pp. 4448-4454 (1998).
Sissman et al., “Patent Ductus Arteriosus, Prematurity, and Respiratory Distress Syndrome”,JAMA, vol. 261, No. 23, pp. 3410 (1989).
Weitz et al., “Diagnosis and Treatment of Chronic Arterial Insuficiency of the Lower Extremities: A Critical Review”,Circulation, vol. 94, pp. 3026-2049 (1996).
Partial European Search Report dated Jan. 13, 2005 issued in European Patent Application No. 04027507.5.
Apstein, C., Circulation, vol. 98, Nov. 24, 1998, pp 2223-2226.
Coolidge Thomas R.
Ehlers Mario R. W.
Amylin Pharmaceuticals Inc.
Arnold & Porter LLP
Carlson Karen Cochrane
Liu Samuel W.
LandOfFree
Metabolic intervention with GLP-1 to improve the function of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metabolic intervention with GLP-1 to improve the function of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metabolic intervention with GLP-1 to improve the function of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586910